undamentalytics Newsletter
Sign in

Azenta, Inc. (AZTA) stock

Add to watchlist

Add holding +

NASDAQ: AZTA Nasdaq Life Sciences Tools & Services Next results ~November 10, 2026

C+ Fundamentals grade

Azenta, Inc. is a US-listed company in the life sciences tools & services industry. Its financial year ends in September.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: our cash-flow value ($16.97) is 0.33x the median of our other models ($51.72); a gap this wide usually means the cash flow is temporarily depressed (heavy investment, a one-off payment).

Price vs value

Under review: our cash-flow value ($16.97) is 0.33x the median of our other models ($51.72); a gap this wide usually means the cash flow is temporarily depressed (heavy investment, a one-off payment). We'll show the comparison once resolved.

Azenta, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

Value diary

Our note on each quarter Azenta files

Where Azenta stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $614m, up 4.9% on a year earlier, faster than the 1.8% growth a quarter earlier. Free-cash-flow margin fell to 1.6% from 8.9% a year earlier. Operating margin narrowed to -28.6% from -5.7%. Against its peers on growth, profitability, cash generation and balance sheet, it grades C. It passes 2 of our 2 financial-health checks.

Our model value for Azenta is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 6, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 10, 2026 (estimated)

Azenta, Inc.'s trailing-twelve-month revenue grew 4.9% year on year, with a free-cash-flow margin of 1.6%. Where it lags: days sales outstanding of 85 days ranks 42 of 48 life sciences tools & services companies we cover.

Our discounted-cash-flow model values the business at ~$17 per share in the base case (~$16–$19 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Free cash flow diverging from earnings: TTM free cash flow fell 81.1% while net income fell 8.5%: a 73pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Growth speeding up. The growth rate is 3.0 points higher than a quarter earlier.
  • Shrinking share count. Diluted shares fell 1.1% in a year, so each share owns more of the business.
  • Net cash. Cash exceeds long-term debt by $0.2bn.

Things to watch

  • Loss-making. Operating margin is -28.6%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 22.9 points on a year ago.
  • Volatile shares. Over the past year the shares showed annualised volatility of 64% and a beta of 1.6 against the S&P 500.
  • Below peers: days sales outstanding. Days sales outstanding of 85 days ranks 42 of 48 life sciences tools & services companies we cover (median 62 days).
  • Heavily shorted. 19.9% of the shares available to trade are sold short (4.4 days of average volume to cover).
  • Missing expectations. Earnings per share fell short of the consensus estimate in 2 of the last four quarters.

Latest results: FY2026 Q3

Filed August 6, 2026
Earnings per share
$0.16 against an average estimate of $0.10: beat by 60.0%
Revenue
$161m, up 12.0% on a year earlier
Share reaction
+6.5% in the first session after the results on August 4, 2026, against +1.6% for the S&P 500
Guidance given
adjusted EBITDA $20m to $23m (Fourth Quarter Fiscal 2026); total reported revenue from continuing operations $613m to $618m (Full Year Fiscal 2026)
Next report
November 10, 2026; average EPS estimate $0.11

Azenta's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-9.0%
  • 1 week-4.4%
  • 1 month-8.3%
  • This year+6.9%
  • 1 year+17.7%
  • 5 years-70.5%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$614M
Operating margin
-28.6%
Net margin
-20.0%
EPS (TTM, diluted)
$-2.68

Growth

Revenue growth
+4.9%
Change in growth rate
+3.0 pts
Share count change
−1.1%

Cash

Free cash flow (TTM)
$9.9M
FCF margin
1.6%
Stock pay % of revenue
3.1%

Earnings

Last results
August 4, 2026
Next results (est.)
November 20, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Agreement
  3. Restructuring
  4. Leadership
  5. Announcement
  6. Leadership
  7. Leadership
  8. Results
  9. Guidance
  10. Deal

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Azenta, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: held for review: our cash-flow value ($16.97) is 0.33x the median of our other models ($51.72); a gap this wide usually means the cash flow is temporarily depressed (heavy investment, a one-off payment).

Our value per share comes from a discounted-cash-flow model of Azenta, Inc.'s free cash flow after stock-based pay ( $12.7M, FY2026 Q3 TTM, with after-tax interest added back): growth for five years as below (the first two years from forecasts, guidance and the company's record), fading to 2.5%, discounted at 8.5%, then cash added and debt and other claims subtracted. These are model values under stated assumptions, not price targets or recommendations.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Azenta, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.8%: the 10-year Treasury yield (4.9%) plus a beta of 1.08 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Cash-flow model (DCF) Free cash flow to the firm (after stock pay, with after-tax interest added back), grown then faded to 2.5%, discounted at 8.5% as the firm rate, less debt and other claims. ~$17 ~$16–$19 Primary model, counts double
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$12 ~$9.5–$17 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. ~$52 ~$39–$70 Included
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. ~$56 ~$49–$65 Included
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Azenta, Inc. with Life Sciences Tools & Services in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 2016201720182019202020212022202320242025Now
Share price$12.83$29.15$34.09$36.47$46.00$102.26$42.86$50.19$48.44$28.72$35.55
Market value$879m$2.1bn$2.4bn$2.6bn$3.4bn$7.6bn$3.2bn$3.3bn$2.6bn$1.3bn$1.6bn
+ Net debt (− = net cash)−$85m−$102m$792000−$205m−$200m−$177m−$658m−$649m−$280m−$280m−$190m
Enterprise value$794m$2.0bn$2.4bn$2.4bn$3.2bn$7.4bn$2.6bn$2.7bn$2.3bn$1.0bn$1.4bn
Multiples
Price / sales 2.0x3.9x3.8x7.9x8.7x14.8x5.8x6.0x4.5x2.2x2.7x
Price / earnings —32.8x20.7x6.0x52.4x68.7x1.5x————
Price / free cash flow 32.9x24.6x39.5x39.4x—78.5x——n/m34.4x164.8x
EV / EBITDA 72.2x46.0x35.1xn/m110.6xn/m88.1x109.9x58.2x30.2x—

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

46 /100

Moderate moat

How hard Azenta's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Cash operating profit has been a median 0.1% of total assets over 10 years.

  • Pricing power 12 / 20

    Gross margin has been a median 44.8%, moving by 5.0 percentage points (standard deviation) across 10 years.

  • Durability 10 / 20

    Operating margin has been a median -5.7%; its worst year was -359.6%.

  • Cash conversion 10 / 20

    Free cash flow was positive in 7 of 10 years, at a median 6.7% of revenue.

  • Discipline 19 / 20

    The diluted share count fell 38.3% over five years; stock-based pay has been a median 3.1% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (51 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 10, 2026, after the close. Analysts expect revenue of $160m and EPS of $0.11 (range $0.05 to $0.15) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $0.32 −38% $615m +4%
Next $0.53 +65% $639m +4%

Next year's EPS estimate has moved −14.3% in 90 days, across 5 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −15.8% on 90 days ago. In the last 30 days, 0 analysts raised Azenta, Inc.'s forecast and 3 cut it.

Consensus EPS forecast Azenta, Inc., last 90 days
$0.30 $0.40 $0.50 $0.60 $0.70 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $0.38 Current fiscal year, 60 days ago: $0.37 Current fiscal year, 30 days ago: $0.35 Current fiscal year, 7 days ago: $0.32 Current fiscal year, Now: $0.32 $0.32 Next fiscal year, 90 days ago: $0.61 Next fiscal year, 60 days ago: $0.59 Next fiscal year, 30 days ago: $0.59 Next fiscal year, 7 days ago: $0.55 Next fiscal year, Now: $0.53 $0.53

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $0.38$0.61
60 days ago $0.37$0.59
30 days ago $0.35$0.59
7 days ago $0.32$0.55
Now $0.32$0.53

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 $0.10 $0.16 +60.0%
Mar 2026 $0.14 −$0.04 −129.0%
Dec 2025 $0.13 $0.09 −33.0%
Sept 2025 $0.20 $0.21 +7.3%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 4, 2026
  • Total reported revenue from continuing operations Full Year Fiscal 2026 $613m to $618m GAAP
    “The Company now expects total reported revenue from continuing operations to range approximately between $613 to $618 million, compared to prior guidance of $603 to $621 million for the fiscal year ending September 30, 2026.” source
  • Adjusted EBITDA Full Year Fiscal 2026 $59m to $62m Non-GAAP
    “Adjusted EBITDA is expected to be in the range of $59 million to $62 million, including an anticipated impact of approximately 30 basis points of margin dilution from the UK Biocentre acquisition.” source
  • Free cash flow Full Year Fiscal 2026 10% growth to 15% growth Non-GAAP Maintained
    “Free cash flow (cash flow from operations less capital expenditures) is expected to improve approximately 10% to 15% year-over-year, consistent with prior guidance.” source
  • Adjusted EBITDA Fourth Quarter Fiscal 2026 $20m to $23m Non-GAAP
    “Adjusted EBITDA is expected to range approximately between $20 million and $23 million.” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

How our valuation uses these forecasts

Our cash-flow model grows Azenta, Inc.'s revenue by +2.8% next year and +2.6% the year after, then fades back toward its own record by year five. Next year's rate weighs analysts' consensus (+3.1%, weight 52%) , management guidance (+3.3%, weight 21%) and the company's own record (+2.0%, weight 28%) . How the weights are set.

Analyst recommendations

6 analysts, Oct 2026
Buy350%
Hold350%
Sell00%

Monthly trend

  1. Oct 20261236
  2. Sep 20261236
  3. Aug 20261236
  4. Jul 20261236

Counts of recommendations published by analysts covering Azenta, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
19.9%
of tradable shares
Days to cover
4.44
at average volume
Short interest, 1 month
−0%
to October 15, 2026
Held by institutions
—
of shares
Held by insiders
1.3%
of shares
Employees
2,900
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +17.7%

$30.20 on October 31, 2025 to $35.55

ThenNowEffect
Revenue (last 12 months) $585m $614m +4.9%
P/S multiple 2.4x 2.7x +11.1%
Share count 46m 46m +1.1%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

Last 3 years −28.6%

$49.77 on November 3, 2023 to $35.55

ThenNowEffect
Revenue (last 12 months) $630m $614m −2.6%
P/S multiple 5.5x 2.7x −52.0%
Share count 70m 46m +52.7%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
AZTA+53%−44%+12%−23%−34%+7%
Industry peers (median)+4%−53%−3%−13%−2%+16%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
AZTA50%33%50%42%50%64%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
AZTA−28%−63%−41%−40%−54%−61%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 87% from November 8, 2021 to May 15, 2026. Getting back needed a 674% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$16.02 – $42.73
From 52-week high
−16.8%
vs 50-day average
+1.8%
vs 200-day average
+25.4%
Volatility (1 year)
64%
Beta vs S&P 500
1.56

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
5 up, 7 down
typical move ±10.1%
After a week
4 up, 8 down
typical move ±10.4%
After a month
4 up, 8 down
typical move ±11.9%
Results releasedNext dayS&P 500 next day5 days21 days
August 4, 2026 +6.5% +1.6% +11.7% +6.2%
May 5, 2026 −24.5% +2.2% −27.9% −6.1%
February 4, 2026 −24.5% −1.7% −17.5% −34.2%
November 21, 2025 +22.3% +2.5% +16.2% +15.7%
August 5, 2025 −12.4% +0.3% −9.9% −8.9%
May 7, 2025 +9.0% +1.1% +6.0% +13.1%
February 5, 2025 +4.0% +0.8% −12.8% −16.0%
January 30, 2025 +1.2% 0.0% +1.2% −23.0%
November 12, 2024 −2.9% −0.3% −10.8% +0.2%
August 6, 2024 −4.9% +0.2% −2.8% −15.4%
May 8, 2024 −4.8% +0.6% −6.4% −2.1%
February 7, 2024 −4.0% +0.9% −1.7% −2.0%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Azenta, Inc. in five measures

Fundamentals grade C+
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Azenta, Inc.
$450M $500M $550M $600M $650M FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue (TTM), FY23 Q4: $551.5M Revenue (TTM), FY24 Q1: $515.3M Revenue (TTM), FY24 Q2: $503.3M Revenue (TTM), FY24 Q3: $481.6M Revenue (TTM), FY24 Q4: $573.4M Revenue (TTM), FY25 Q1: $578.7M Revenue (TTM), FY25 Q2: $585.7M Revenue (TTM), FY25 Q3: $585.2M Revenue (TTM), FY25 Q4: $593.8M Revenue (TTM), FY26 Q1: $595M Revenue (TTM), FY26 Q2: $596.5M Revenue (TTM), FY26 Q3: $613.8M $613.8M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q4 $551.5M
FY24 Q1 $515.3M
FY24 Q2 $503.3M
FY24 Q3 $481.6M
FY24 Q4 $573.4M
FY25 Q1 $578.7M
FY25 Q2 $585.7M
FY25 Q3 $585.2M
FY25 Q4 $593.8M
FY26 Q1 $595M
FY26 Q2 $596.5M
FY26 Q3 $613.8M
Revenue growth, TTM YoY Azenta, Inc.
-40% -20% 0% 20% 40% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue growth, TTM YoY, FY23 Q4: -0.7% Revenue growth, TTM YoY, FY24 Q1: -13.3% Revenue growth, TTM YoY, FY24 Q2: -15.7% Revenue growth, TTM YoY, FY24 Q3: -23.6% Revenue growth, TTM YoY, FY24 Q4: 4.0% Revenue growth, TTM YoY, FY25 Q1: 12.3% Revenue growth, TTM YoY, FY25 Q2: 16.4% Revenue growth, TTM YoY, FY25 Q3: 21.5% Revenue growth, TTM YoY, FY25 Q4: 3.6% Revenue growth, TTM YoY, FY26 Q1: 2.8% Revenue growth, TTM YoY, FY26 Q2: 1.8% Revenue growth, TTM YoY, FY26 Q3: 4.9% 4.9%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q4 -0.7%
FY24 Q1 -13.3%
FY24 Q2 -15.7%
FY24 Q3 -23.6%
FY24 Q4 4.0%
FY25 Q1 12.3%
FY25 Q2 16.4%
FY25 Q3 21.5%
FY25 Q4 3.6%
FY26 Q1 2.8%
FY26 Q2 1.8%
FY26 Q3 4.9%
Operating margin (TTM) Azenta, Inc.
-30% -20% -10% 0% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Operating margin (TTM), FY23 Q4: -11.1% Operating margin (TTM), FY24 Q1: -9.4% Operating margin (TTM), FY24 Q2: -11.9% Operating margin (TTM), FY24 Q3: -10.7% Operating margin (TTM), FY24 Q4: -8.9% Operating margin (TTM), FY25 Q1: -7.8% Operating margin (TTM), FY25 Q2: -6.6% Operating margin (TTM), FY25 Q3: -5.7% Operating margin (TTM), FY25 Q4: -4.5% Operating margin (TTM), FY26 Q1: -4.3% Operating margin (TTM), FY26 Q2: -29.0% Operating margin (TTM), FY26 Q3: -28.6% -28.6%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q4 -11.1%
FY24 Q1 -9.4%
FY24 Q2 -11.9%
FY24 Q3 -10.7%
FY24 Q4 -8.9%
FY25 Q1 -7.8%
FY25 Q2 -6.6%
FY25 Q3 -5.7%
FY25 Q4 -4.5%
FY26 Q1 -4.3%
FY26 Q2 -29.0%
FY26 Q3 -28.6%
FCF margin (TTM) Azenta, Inc.
-10% -5% 0% 5% 10% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 FCF margin (TTM), FY23 Q4: -6.1% FCF margin (TTM), FY24 Q1: 1.7% FCF margin (TTM), FY24 Q2: 6.3% FCF margin (TTM), FY24 Q3: 4.4% FCF margin (TTM), FY24 Q4: 2.2% FCF margin (TTM), FY25 Q1: 5.5% FCF margin (TTM), FY25 Q2: 6.6% FCF margin (TTM), FY25 Q3: 8.9% FCF margin (TTM), FY25 Q4: 6.5% FCF margin (TTM), FY26 Q1: 5.2% FCF margin (TTM), FY26 Q2: 5.0% FCF margin (TTM), FY26 Q3: 1.6% 1.6%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q4 -6.1%
FY24 Q1 1.7%
FY24 Q2 6.3%
FY24 Q3 4.4%
FY24 Q4 2.2%
FY25 Q1 5.5%
FY25 Q2 6.6%
FY25 Q3 8.9%
FY25 Q4 6.5%
FY26 Q1 5.2%
FY26 Q2 5.0%
FY26 Q3 1.6%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2009 Sept 2009 2010 Sept 2010 2011 Sept 2011 2012 Sept 2012 2013 Sept 2013 2014 Sept 2014 2015 Sept 2015 2016 Sept 2016 2017 Sept 2017 2018 Sept 2018 2019 Sept 2019 2020 Sept 2020 2021 Sept 2021 2022 Sept 2022 2023 Sept 2023 2024 Sept 2024 2025 Sept 2025 LTM Jun 2026
Income
Revenue 219 593 688 489 422 483 553 434 527 632 334 389 514 555 551 573 594 614
Gross profit −6 166 223 159 132 167 189 157 199 246 135 172 244 256 239 255 270 270
EBITDA −202 65 97 23 7 21 42 11 42 69 7 29 34 29 24 39 34 −120
Operating income −228 47 80 2 −17 −3 17 −17 14 31 −47 −37 −31 −25 −61 −51 −27 −175
Net income −228 60 130 137 −2 31 14 −69 63 117 437 65 111 2,133 −15 −165 −56 −123
Diluted EPS −$3.62 $0.93 $2.01 $2.08 −$0.03 $0.46 $0.21 −$1.01 $0.89 $1.64 $6.04 $0.88 $1.49 $28.48 −$0.22 −$3.10 −$1.22 −$2.68
Growth (year on year)
Revenue — +171.1% +16.0% −28.9% −13.6% +14.3% +14.5% −21.5% +21.5% +19.7% −47.1% +16.3% +32.2% +8.1% −0.7% +4.0% +3.6% +4.9%
EBITDA — — +48.0% −76.0% −68.4% — +102.6% −73.9% +286.4% +62.1% −89.8% +311.4% +18.5% −15.4% −16.0% +62.1% −12.9% −421.3%
Operating income — — +69.3% −97.9% — — — −201.0% — +119.4% −251.0% — — — — — — —
Net income — — +117.9% +4.9% −101.6% — −54.7% −588.5% — +86.2% +275.2% −85.2% +70.8% +>999% −100.7% — — —
Diluted EPS — — +116.1% +3.5% −101.4% — −54.3% −581.0% — +84.3% +268.3% −85.4% +69.3% +>999% −100.8% — — —
Margins
Gross margin −2.7% 28.0% 32.4% 32.6% 31.3% 34.7% 34.2% 36.1% 37.7% 39.0% 40.3% 44.3% 47.5% 46.0% 43.4% 44.4% 45.5% 44.0%
EBITDA margin −92.4% 11.0% 14.1% 4.8% 1.7% 4.3% 7.6% 2.5% 8.1% 10.9% 2.1% 7.4% 6.7% 5.2% 4.4% 6.9% 5.8% −19.5%
Operating margin −104.3% 7.9% 11.6% 0.3% −4.0% −0.6% 3.1% −3.9% 2.7% 5.0% −14.2% −9.4% −6.1% −4.5% −11.1% −8.9% −4.5% −28.6%
Net margin −104.1% 10.1% 18.9% 28.0% −0.5% 6.5% 2.6% −16.0% 11.9% 18.5% 130.9% 16.7% 21.6% 384.0% −2.7% −28.8% −9.4% −20.0%
Free-cash-flow margin −31.0% 4.1% 11.8% 5.6% 12.0% 10.0% 5.0% 6.2% 15.8% 9.7% 20.1% −0.5% 18.9% −97.1% −6.1% 2.2% 6.5% 1.6%
Cash flow
Cash from operations −56 28 88 36 54 54 44 40 96 74 91 38 150 −466 6 50 72 38
Capital spending 11 3 6 9 4 6 16 13 13 13 24 40 53 73 39 37 34 28
Free cash flow −68 24 81 27 51 48 28 27 84 61 67 −2 97 −539 −34 12 38 10
Stock-based pay 6 7 7 9 8 11 12 12 17 20 20 16 27 11 9 14 21 19
Free cash flow after stock pay −74 18 74 19 43 37 15 15 66 41 47 −18 70 −550 −43 −2 17 −9
Balance sheet
Cash 60 60 59 55 83 94 81 85 102 198 257 251 227 658 649 280 280 190
Total debt 0 0 0 0 0 0 0 0 0 199 52 51 50 — 0 0 0 0
Net debt (negative = net cash) −60 −60 −59 −55 −83 −94 −81 −85 −102 1 −205 −200 −177 −658 −649 −280 −280 −190
Diluted shares 63m 64m 65m 66m 66m 68m 69m 69m 70m 71m 72m 74m 74m 75m 66m 53m 46m 46m
Returned to shareholders
Dividends — — 5 21 21 23 27 28 28 28 29 30 30 7 0 0 — —
Buybacks — — — — — — — — — — — — — 0 839 662 0 —
Total returned — — 5 21 21 23 27 28 28 28 29 30 30 7 839 662 0 —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $1.9bn
Short-term assets $681mLonger-term assets $1.2bn
What it owes, and who funded it · $1.9bn
Short-term liabilities $273mLonger-term liabilities $94mShareholders' equity $1.5bn
  • Short-term assets cover short-term liabilities $681m of assets due within a year against $273m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $681m short-term assets against $94m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Azenta, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

FY2025 Q4 TTM
Buybacks (TTM)
$0
Buybacks, last 3 fiscal years
$1.5B
Diluted share count
−1.1%
year over year
Total shareholder yield
0.0%
dividends 0.0% + buybacks 0.0% of market value
R&D spending
5.8%
of revenue
Sales & admin spending
41.9%
of revenue
Days sales outstanding
85 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in life sciences tools & services
Last 12 months unless stated AZTA TXG VCYT NEO RGEN TWST Median
Revenue, last 12 months $614m $617m $562m $788m $806m $432m $229m
Revenue growth, last 12 months 4.9% −4.3% 17.3% 11.1% 13.8% 19.2% 6.9%
Revenue growth, 3-year average −0.9% 2.8% 19.6% 11.1% 7.3% 22.4% 2.9%
Revenue growth, latest quarter 12.0% −12.6% 15.5% 11.4% 10.9% 23.2% 8.5%
Gross margin 44.0% 70.0% 71.7% 44.8% 53.5% 52.0% 51.9%
Operating margin −28.6% −14.3% 18.8% −6.3% 2.3% −33.6% −14.3%
Operating margin, 3-year average −15.0% −23.3% 1.6% −12.5% 1.4% −50.8% −22.4%
Net margin −20.0% −12.2% 20.4% −4.1% −1.5% −31.7% −16.1%
Cash from operations / revenue 6.2% 20.6% 31.7% 0.5% 16.1% −12.3% 1.3%
Free-cash-flow margin 1.6% 19.7% 29.5% −3.6% 13.2% −21.6% −2.2%
Free-cash-flow margin, 3-year average 5.0% 7.8% 19.0% −3.1% 16.6% −22.0% 0.6%
Stock pay / revenue 3.1% 16.0% 8.6% 4.4% 4.2% 15.4% 4.4%
Change in share count −1.1% 4.2% 2.5% 1.2% 0.3% 2.4% 1.0%

Median of all 54 companies we cover in life sciences tools & services. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

54 life sciences tools & services companies
Measure Company Peer median Rank
Revenue growth Growth 4.9% 6.9% 34 of 54
Change in growth rate Growth +3.0pp +0.4pp 13 of 54
Gross margin Profitability 44.0% 52.0% 31 of 45
Operating margin Profitability -28.6% -14.3% 31 of 52
Net margin Profitability -20.0% -12.2% 28 of 54
Free-cash-flow margin Cash generation 1.6% -1.3% 23 of 54
Stock pay as % of revenue Cash generation 3.1% 4.4% 21 of 53
Change in share count Balance sheet -1.1% 1.0% 14 of 46
Days sales outstanding Balance sheet 85 days 62 days 42 of 48

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to September 30, 2025
Segments
Line of business Revenue Share YoY
Sample Management Solutions $325M 54.7% ▲ 1.8%
Core Products $198M 60.9% ▲ 0.6%
Sample Repository Solutions $127M 39.1% ▲ 3.7%
Multiomics $269M 45.3% ▲ 5.8%
Products and services
Line of business Revenue Share YoY
Services $421M 70.8% ▲ 5.2%
Products $173M 29.2% ▼ 0.3%
Geography
Region Revenue Share YoY
United States $365M 61.5% 0.0%
Europe $107M 18.1% ▲ 12.8%
China $58.3M 9.8% ▲ 0.2%
United Kingdom $35.4M 6.0% ▲ 30.1%
Asia Pacific $23.3M 3.9% ▲ 9.2%
Other $4.4M 0.7% ▼ 31.5%

From Azenta, Inc.'s 10-K filed December 4, 2025, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$1.3B
Institutions reporting
248
Shares held vs prior quarter
▼ 5.9%
Positions opened / closed
40 / 51

Top buyers and sellers, Q2 2026: 134 institutions bought and 131 sold ; the biggest buyer was Snyder Capital Management L P (+839K shares) and the biggest seller Conestoga Capital Advisors, LLC (−2.8M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $192M 7.5M 15.0% ▲ 12.0%
Politan Capital Management LP $118M 4.6M 9.2% 0.0%
Vanguard Portfolio Management LLC $63.6M 2.5M 5.0% ▲ 1.8%
Vanguard Capital Management LLC $47.7M 1.9M 3.7% ▲ 2.3%
State Street Corp $47.5M 1.9M 3.7% ▲ 5.5%
Massachusetts Financial Services Co $36.3M 1.4M 2.8% ▼ 20.4%
D. E. Shaw & Co., Inc. $34.2M 1.3M 2.7% ▲ 97.5%
Morgan Stanley $33.9M 1.3M 2.6% ▲ 53.7%
Front Street Capital Management, Inc. $33.2M 1.3M 2.6% ▲ 46.4%
Dimensional Fund Advisors LP $31.5M 1.2M 2.5% ▼ 40.2%
Allspring Global Investments Holdings, LLC $31.2M 1.2M 2.4% ▼ 26.1%
Neuberger Berman Group LLC $28.9M 1.1M 2.3% ▲ 25.3%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Azenta, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $171,897 2 trades by 2 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $171,897 net buying
Insider Date Trade Shares Price Value
Starr Ephraim SVP, Gen Counsel & Secretary July 31, 2026 Buy 335 $24.17 $8,097
Cornog William L Director May 18, 2026 Buy 10,000 $16.38 $163,800

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 9 trades and filings

In the last 12 months, 1 member of Congress disclosed 2 purchases and 0 sales of Azenta, Inc. shares.

  • Gilbert Ray Cisneros, Jr.(D-CA 31):Purchase, $1,001 - $15,000, traded March 3, 2026, filed April 7, 2026
  • Gilbert Ray Cisneros, Jr.(D-CA 31):Purchase, $1,001 - $15,000, traded January 15, 2026, filed February 13, 2026
  • Gilbert Ray Cisneros, Jr.(D-CA 31):Purchase, $1,001 - $15,000, traded October 9, 2025, filed November 18, 2025

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around November 20, 2026 estimated from the company's past filing pattern, not announced

  • August 4, 2026
  • May 5, 2026
  • February 4, 2026
  • November 21, 2025
  • August 5, 2025
  • May 7, 2025

Recent SEC filings

Data status

When each part of this page on Azenta, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Azenta, Inc. in brief

What does Azenta, Inc. do?
Azenta, Inc. is a US-listed company in the life sciences tools & services industry. Its financial year ends in September.
What is Azenta, Inc.'s stock ticker?
Azenta, Inc. trades under the ticker AZTA on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Azenta, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Azenta, Inc. reported revenue of $614M, 4.9% higher than a year earlier, according to its SEC filings.
What is Azenta, Inc.'s free cash flow?
Azenta, Inc.'s free-cash-flow margin is 1.6% of revenue over the trailing twelve months, ranking 23 of the 54 life sciences tools & services companies we cover.
Who are Azenta, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., Politan Capital Management LP and Vanguard Portfolio Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Is Azenta, Inc. buying back stock, and does it pay a dividend?
Azenta, Inc. spent $0 on share repurchases over the trailing twelve months, and its diluted share count fell 1.1% over the year.
What is Azenta, Inc.'s market cap?
On November 2, 2026, Azenta, Inc.'s market capitalisation was about $1.6B and net debt of -$190M. Market figures come from third-party market data and may be delayed.
Who are Azenta, Inc.'s competitors?
In our Life Sciences Tools & Services peer group, the companies closest to Azenta, Inc. are 10x Genomics, Inc., Veracyte, Inc., Neogenomics Inc, Repligen Corp and Twist Bioscience Corp. The side-by-side comparison below sets their revenue, margins and growth against Azenta, Inc.'s.
Are insiders buying or selling Azenta, Inc. stock?
Over the last 12 months, Azenta, Inc.'s directors and officers reported 2 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
When is Azenta, Inc.'s next earnings date?
Around November 10, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Azenta, Inc. announces its own schedule.